Alexander Melamud, MD
Retina Specialist · Fairfax, VANPI 1669573788
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,861 of the $6,222 with a category attached, or 62.0%. 20 manufacturers reported payments, led by Eyepoint US, Inc. at 26.7% of the total. Reporting peaked in 2024 at $3,370 and has fallen 73.2% since, to $901 in 2025.
Across 104 payments — averaging $59.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eyepoint US, Inc.$2K
- Dutch Ophthalmic, USA$986
- AbbVie$516
- Genentech, Inc.$415
- Regeneron Healthcare Solutions, Inc.$413
- Genentech USA, Inc.$360
- plus $2K from 14 others
Across 26 payments — averaging $40,250 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$943K
- Eyepoint US, Inc.$72K
- Astellas Pharma Global Development$18K
- Roche TCRC, Inc.$13K
- Notal Vision, Inc.$360
What the payments were for
- Travel & lodging$2,36238%
- Food & beverage$3,86162%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eyepoint US, Inc. | 6 | $1,661 |
| Dutch Ophthalmic, USA | 3 | $986 |
| AbbVie(2 entities) | 18 | $516 |
| Genentech, Inc. | 6 | $415 |
| Regeneron Healthcare Solutions, Inc. | 12 | $413 |
| Genentech USA, Inc. | 16 | $360 |
| Astellas Pharma US Inc | 11 | $344 |
| Apellis Pharmaceuticals, Inc. | 6 | $268 |
| Alcon | 2 | $235 |
| Rxsight Inc | 2 | $151 |
| Novartis | 6 | $149 |
| Coopervision Inc. | 1 | $143 |
| Biotissue Holdings Inc. | 1 | $137 |
| Tarsus Pharmaceuticals, Inc. | 1 | $136 |
| Coherus Oncology, Inc. | 3 | $87 |
| ANI Pharmaceuticals, Inc. | 2 | $62 |
| Bausch & Lomb Americas Inc. | 3 | $59 |
| Astellas Pharma Global Development | 2 | $58 |
| Alimera Sciences, Inc. | 2 | $41 |
| Notal Vision, Inc. | 1 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYP-1901$1,585
- EVA, combined machine$840
- TISSUEBLUE$840
- SUSVIMO$150
- MiSight Contact Lens$143
- Prokera$137
- XDEMVY$136
- ReSTOR$120
- TRYPTYR$115
- OZURDEX$111
- Syfovre$103
How this compares
$6,222 in reported general payments places this provider in the 75th percentile of 41 retina specialist providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Loteprednol Etabonate | 15 | $4,986 |
| Prednisolone Acetate | 52 | $2,527 |
| Difluprednate | 19 | $1,749 |
| Ketorolac Tromethamine | 19 | $434 |
| Ofloxacin | 21 | $243 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Fairfax
- Jiwei ShengFairfax$8K
- John MinarcikFairfax$805
- Amir HaririFairfax$556
- Samuel YunFairfax$51
- Jordana FeinManassas$412K
- Joaquin TosiVirginia Beach$48K
- Mohit NandaCharlottesville$31K
- Muge KesenMc Lean$30K
- Anna MackinRoanoke$26K
- Jon AdlebergChesapeake$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.